Literature DB >> 1309303

Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity.

G Cavaletti1, L Marzorati, G Bogliun, N Colombo, M Marzola, M R Pittelli, G Tredici.   

Abstract

The authors prospectively evaluated the effects of three different schedules of cisplatin (DDP) administration in 60 patients with advanced epithelial ovarian cancer. The individual total dose of DDP was 450 mg/m2 in all three groups, and the anti-cancer response at the end of treatment was similar for the different regimens. The clinical and neurophysiologic results confirmed that axonal sensory neuropathy occurred after the standard administration of DDP (75 mg/m2 in 3-week cycles) and probably not only the peripheral, but also the central sensory pathway, was involved. Although the total dose of the drug was identical, the two less conventional schedules were less neurotoxic. These results suggest that not only the total-dose intensity, but also the single-dose intensity are relevant in the onset of DDP-induced sensory neuropathy; therefore, the use of less neurotoxic schedules may prevent or reduce sensory nerve damage.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1309303     DOI: 10.1002/1097-0142(19920101)69:1<203::aid-cncr2820690133>3.0.co;2-1

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  28 in total

1.  Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate.

Authors:  F M Boyle; H R Wheeler; G M Shenfield
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

2.  Neurologic Complications of Cancer Therapy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-11       Impact factor: 3.598

Review 3.  Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications.

Authors:  Julienne E Bower; Donald M Lamkin
Journal:  Brain Behav Immun       Date:  2012-07-06       Impact factor: 7.217

4.  Experimental cisplatin neuronopathy in rats and the effect of retinoic acid administration.

Authors:  G Tredici; S Tredici; D Fabbrica; C Minoia; G Cavaletti
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

5.  Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy with paclitaxel for advanced gastric cancer.

Authors:  Ryo Otsuka; Satoru Iwasa; Takako Yanai; Hidekazu Hirano; Hirokazu Shoji; Yoshitaka Honma; Natsuko Okita; Atsuo Takashima; Ken Kato; Hironobu Hashimoto; Masatoshi Sekiguchi; Yoshinori Makino; Narikazu Boku; Masakazu Yamaguchi
Journal:  Int J Clin Oncol       Date:  2019-12-18       Impact factor: 3.402

Review 6.  Chemotherapy-induced peripheral neuropathy: underreported and underappreciated.

Authors:  Maurie Markman
Journal:  Curr Pain Headache Rep       Date:  2006-08

Review 7.  Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment.

Authors:  Nathan P Staff; Guido Cavaletti; Badrul Islam; Maryam Lustberg; Dimitri Psimaras; Stefano Tamburin
Journal:  J Peripher Nerv Syst       Date:  2019-10       Impact factor: 3.494

8.  Persistent hyperalgesia in the cisplatin-treated mouse as defined by threshold measures, the conditioned place preference paradigm, and changes in dorsal root ganglia activated transcription factor 3: the effects of gabapentin, ketorolac, and etanercept.

Authors:  Hue Jung Park; Jennifer A Stokes; Elaine Pirie; James Skahen; Yuri Shtaerman; Tony L Yaksh
Journal:  Anesth Analg       Date:  2012-12-07       Impact factor: 5.108

9.  Evaluation by somatosensory evoked potentials of the neurotoxicity of cisplatin alone or in combination with glutathione.

Authors:  G Bogliun; L Marzorati; G Cavaletti; L Frattola
Journal:  Ital J Neurol Sci       Date:  1992-11

10.  Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients.

Authors:  F E de Jongh; R N van Veen; S J Veltman; R de Wit; M E L van der Burg; M J van den Bent; A S Th Planting; W J Graveland; G Stoter; J Verweij
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.